Valeant Pharmaceuticals Intl Inc (VRX) : Gvo Asset Management Ltd scooped up 570 additional shares in Valeant Pharmaceuticals Intl Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 14, 2016. The investment management firm now holds a total of 245,653 shares of Valeant Pharmaceuticals Intl Inc which is valued at $5,772,846.Valeant Pharmaceuticals Intl Inc makes up approximately 0.65% of Gvo Asset Management Ltd’s portfolio.
Other Hedge Funds, Including , Hartford Financial Management added VRX to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $2,286. Gillespie Robinson Grimm Inc sold out all of its stake in VRX during the most recent quarter. The investment firm sold 137,418 shares of VRX which is valued $2,970,977. Douglass Winthrop Advisors added VRX to its portfolio by purchasing 118,137 company shares during the most recent quarter which is valued at $2,554,122. Valeant Pharmaceuticals Intl Inc makes up approx 0.19% of Douglass Winthrop Advisors’s portfolio.Creative Planning boosted its stake in VRX in the latest quarter, The investment management firm added 79,596 additional shares and now holds a total of 234,055 shares of Valeant Pharmaceuticals Intl Inc which is valued at $5,060,269. Valeant Pharmaceuticals Intl Inc makes up approx 0.04% of Creative Planning’s portfolio.
Valeant Pharmaceuticals Intl Inc opened for trading at $22.77 and hit $24.25 on the upside on Monday, eventually ending the session at $23.5, with a gain of 2.80% or 0.64 points. The heightened volatility saw the trading volume jump to 2,39,79,680 shares. Company has a market cap of $8,061 M.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.27 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Jun 7, 2016. Analyst had a consensus of $1.37. The company had revenue of $2371.60 million for the quarter, compared to analysts expectations of $2337.60 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Valeant Pharmaceuticals Intl Inc was Downgraded by JP Morgan to ” Neutral” on Jun 23, 2016. Shares were Reiterated by RBC Capital Mkts on Jun 8, 2016 to “Sector Perform” and Lowered the Price Target to $ 33 from a previous price target of $58 .Shares were Reiterated by Stifel on Jun 8, 2016 to “Buy” and Lowered the Price Target to $ 55 from a previous price target of $65 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.